At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr James Chih-Hsin Yang presented a phase III international trial that found initial single-agent oral therapy with the targeted drug afatinib prolongs progression-free survival in patients with advanced lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR, also known as ErbB1) mutations, compared with standard chemotherapy.